ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

difamilast

Also written as “OPA-15406”, “1% OPA-15406 Ointment” and “0.3% OPA-15406 Ointment”.

Its studies are mostly in Dermatitis, Atopic, led by 3 companies.

Drug pageDifamilast: every studyAll 16 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Apr 7, 201916 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Otsuka132 open or runningphase 3since Apr 7, 2019Oct 3, 2012Dec 2026phase 3 · NCT07173478
Aurobindo Pharmaits history only20 open or runningphase 3since Oct 5, 2022Oct 5, 2022none ahead
Eurofarma Laboratoriosits history only10 open or runningphase 2since Oct 21, 2016Oct 21, 2016none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Otsuka only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Oct 3, 2012First study: phase 1 study in Dermatitis, AtopicFirst studyNCT01702181 · 92 enrolled · United States
  2. Feb 19, 2014Phase 2 study in Dermatitis, AtopicNCT02068352 · 121 enrolled · United States, Australia, Poland
  3. Jan 5, 2015Phase 1 study in Dermatitis, AtopicNCT02334787 · 32 enrolled · Japan
  4. Sep 8, 2016Phase 2 study in Dermatitis, AtopicNCT02914548 · 200 enrolled · Japan
  5. Jan 6, 2017Phase 2 study in Dermatitis, AtopicNCT03018691 · 73 enrolled · Japan
  6. Dec 9, 2017Named difamilastINNProposed as its International Nonproprietary Name in WHO's List 118 · before, OPA-15406
  7. Apr 7, 20193 phase 3 studies in Dermatitis, AtopicNCT03908970, NCT03911401, NCT03961529
  8. May 9, 2022Phase 3 study in Dermatitis, AtopicNCT05372653 · 41 enrolled · Japan
  9. Dec 2, 20222 phase 3 studies in Dermatitis, AtopicNCT05667623, NCT05650320
  10. Sep 7, 20252 phase 3 studies in Dermatitis, AtopicNCT07173478, NCT07184645

Ahead

  1. Dec 2026Primary completion: phase 3 study in Dermatitis, AtopicNCT07173478
  2. Feb 2027Primary completion: phase 3 study in Dermatitis, AtopicNCT07184645

TargetBeta

“Phosphodiesterase 4 inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
RoflumilastruleAstraZenecaphase 461
apremilastruleAmgenphase 448
ensifentrineruleMerckphase 317
tanimilastruleChiesi Farmaceuticiphase 315

Studies

All 13 Otsuka leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07184645Dermatitis, Atopic · Japan3Not yet recruitingFeb 2027198
NCT07173478Dermatitis, Atopic · Japan3Not yet recruitingDec 2026156
NCT05650320Dermatitis, Atopic · China3CompletedJul 21, 2024240
NCT05667623Dermatitis, Atopic · China3CompletedJun 17, 2024270
NCT05372653Dermatitis, Atopic · Japan3CompletedDec 29, 202241
NCT03961529Dermatitis, Atopic · Japan3CompletedNov 11, 2020366
NCT03911401Dermatitis, Atopic · Japan3CompletedDec 13, 2019251
NCT03908970Dermatitis, Atopic · Japan3CompletedDec 28, 2019364
NCT03018691Dermatitis, Atopic · Japan2CompletedJun 201773
NCT02914548Dermatitis, Atopic · Japan2CompletedJun 2017200
NCT02334787Dermatitis, Atopic · Japan1CompletedFeb 201532
NCT02068352Dermatitis, Atopic · United States, Australia, Poland2CompletedJan 28, 2015121
NCT01702181Dermatitis, Atopic · United States1CompletedDec 201392

How it is read

Names in the registry

  • “OPA-15406”, 7 entries
  • “1% OPA-15406 Ointment”, 3 entries
  • “0.3% OPA-15406 Ointment”, 2 entries
  • “Difamilast”, 2 entries
  • “1% OPA-15406”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.